Education
About Us
Working with TipRanks
Follow Us
Chemomab Therapeutics (CMMB)
NASDAQ:CMMB
Total Valuation
Chemomab Therapeutics has a market cap or net worth of $26.41M. The enterprise value is ―.
Market Cap$26.41M
Enterprise Value―
Share Statistics
Chemomab Therapeutics has 18,856,611 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding18,856,611
Owned by Insiders―
Owned by Institutions18.69%
Financial Efficiency
Chemomab Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.11%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.11%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee0.00
Profits Per Employee-697.25K
Employee Count20
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Chemomab Therapeutics is -105.34. Chemomab Therapeutics’s PEG ratio is <0.01.
PE Ratio-105.34
PS Ratio0.00
PB Ratio0.08
Price to Fair Value0.11
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio<0.01
Income Statement
In the last 12 months, Chemomab Therapeutics had revenue of 0.00 and earned -13.95K in profits. Earnings per share was 0.00.
Revenue0.00
Gross Profit0.00
Operating Income-14.74K
Pretax Income-13.95K
Net Income-13.95K
EBITDA-14.67K
Earnings Per Share (EPS)0.00
Cash Flow
In the last 12 months, operating cash flow was 0.00 and capital expenditures 0.00, giving a free cash flow of 0.00 billion.
Operating Cash Flow0.00
Free Cash Flow0.00
Free Cash Flow per Share0.00
Dividends & Yields
Chemomab Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.59
52-Week Price Change47.37%
50-Day Moving Average1.23
200-Day Moving Average1.57
Relative Strength Index (RSI)59.79
Average Volume (3m)101.64K
Important Dates
Chemomab Therapeutics upcoming earnings date is Aug 8, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
Chemomab Therapeutics as a current ratio of 4.98, with Debt / Equity ratio of 2.39%
Current Ratio4.98
Quick Ratio4.98
Debt to Market Cap0.00
Net Debt to EBITDA391.70
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Chemomab Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Chemomab Therapeutics EV to EBITDA ratio is -1.61K, with an EV/FCF ratio of -1.54.
EV to Sales0.00
EV to EBITDA-1.61K
EV to Free Cash Flow-1.54
EV to Operating Cash Flow-1.54
Balance Sheet
Chemomab Therapeutics has $14.27M in cash and marketable securities with $324.00K in debt, giving a net cash position of -$13.94M billion.
Cash & Marketable Securities$14.27M
Total Debt$324.00K
Net Cash-$13.94M
Net Cash Per Share-$0.74
Tangible Book Value Per Share$0.83
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Chemomab Therapeutics is $8.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$8.50
Price Target Upside507.14% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast57.93%